stockportfolio.pro
Stocks / EBS vs PRTA
EBS vs PRTA
Emergent BioSolutions Inc. and Prothena Corporation plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Emergent BioSolutions Inc. (EBS) | Prothena Corporation plc (PRTA) | |
|---|---|---|
| Market cap | $0.4B | $0.4B |
| Revenue (latest FY) | $705.20M | $9.68M |
| Net income (latest FY) | $52.60M | $-244.09M |
| Revenue growth (5y CAGR) | -14.9% | 62.6% |
| Net margin | 7.5% | -2520.6% |
| Return on equity | 10.1% | -87.0% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 1 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EBS — free Open PRTA — freeFrequently asked questions
Which is bigger, EBS or PRTA?
Prothena Corporation plc is larger by market capitalization — $0.4B versus $0.4B.
Which grows faster, EBS or PRTA?
Over the last five fiscal years, Prothena Corporation plc grew revenue faster — 62.6%/yr versus -14.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.